Angiotensin receptor blockers and myocardial infarction - These drugs may increase myocardial infarction - and patients may need to be told

被引：136

作者：

Verma, S ^{[1
]}

Strauss, M

机构：

[1] Toronto Gen Hosp, Div Cardiac Surg, Toronto, ON M5G 2C4, Canada

[2] N York Gen Hosp, Div Cardiol, N York, ON M2K 1E1, Canada

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7477期

关键词：

D O I：

10.1136/bmj.329.7477.1248

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1248 / 1249

页数：2

共 12 条

[1] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[3] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:: the CHARM-Alternative trial [J].

Granger, CB ;

McMurray, JJV ;

Yusuf, S ;

Held, P ;

Michelson, EL ;

Olofsson, B ;

Östergren, J ;

Pfeffer, MA ;

Swedberg, K .

LANCET, 2003, 362 (9386) :772-776

[4]

IS GSK, 2004, LANCET, V363, P1919

[5] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].

Julius, S ;

Kjeldsen, SE ;

Weber, M ;

Brunner, HR ;

Ekman, S ;

Hansson, L ;

Hua, TS ;

Laragh, J ;

McInnes, GT ;

Mitchell, L ;

Plat, F ;

Schork, A ;

Smith, B ;

Zanchetti, A .

LANCET, 2004, 363 (9426) :2022-2031

[6] Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?: Implications for therapeutic blockade of the renin-angiotensin system [J].

Lévy, BI .

CIRCULATION, 2004, 109 (01) :8-13

[7] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

[8] The Study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial [J].

Lithell, H ;

Hansson, L ;

Skoog, I ;

Elmfeldt, D ;

Hofman, A ;

Olofsson, B ;

Trenkwalder, P ;

Zanchetti, A .

JOURNAL OF HYPERTENSION, 2003, 21 (05) :875-886

[9] Blood-pressure reduction and cardiovascular risk in HOPE study [J].

Sleight, P ;

Yusuf, S ;

Pogue, J ;

Tsuyuki, R ;

Diaz, R ;

Probstfield, J .

LANCET, 2001, 358 (9299) :2130-2131

[10] Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review [J].

Strippoli, GFM ;

Craig, M ;

Deeks, JJ ;

Schena, FP ;

Craig, JC .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7470) :828-831

← 1 2 →